4BCG
Structure of CDK9 in complex with cyclin T and a 2-amino-4-heteroaryl- pyrimidine inhibitor
Summary for 4BCG
Entry DOI | 10.2210/pdb4bcg/pdb |
Related | 1PF6 4BCF 4BCH 4BCI 4BCJ 4BCK 4BCM 4BCN 4BCO 4BCP 4BCQ |
Descriptor | CYCLIN-DEPENDENT KINASE 9, CYCLIN-T1, 2-[[3-(1,4-diazepan-1-yl)phenyl]amino]-4-[4-methyl-2-(methylamino)-1,3-thiazol-5-yl]pyrimidine-5-carbonitrile, ... (5 entities in total) |
Functional Keywords | transferase-cell cycle complex, cdk-cyclin complex, transcription-protein binding, structure-based drug design, transferase/cell cycle |
Biological source | HOMO SAPIENS (HUMAN) More |
Total number of polymer chains | 2 |
Total formula weight | 68778.23 |
Authors | Hole, A.J.,Baumli, S.,Wang, S.,Endicott, J.A.,Noble, M.E.M. (deposition date: 2012-10-02, release date: 2013-04-17, Last modification date: 2019-05-15) |
Primary citation | Shao, H.,Shi, S.,Huang, S.,Hole, A.,Abbas, A.Y.,Baumli, S.,Liu, X.,Lam, F.,Foley, D.W.,Fischer, P.M.,Noble, M.,Endicott, J.A.,Pepper, C.,Wang, S. Substituted 4-(Thiazol-5-Yl)-2-(Phenylamino)Pyrimidines are Highly Active Cdk9 Inhibitors: Synthesis, X-Ray Crystal Structure, Sar and Anti-Cancer Activities. J.Med.Chem., 56:640-, 2013 Cited by PubMed: 23301767DOI: 10.1021/JM301475F PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (3.085 Å) |
Structure validation
Download full validation report